In ERα-positive breast cancer, AR positivity (expression at both mRNA and protein levels) was significantly correlated with improved disease-free survival (DFS) and overall survival (OS), and tumors with an AR:ERα positivity ratio of >0.87 had the best outcome. This evidence concerns the gene AR and breast carcinoma.